Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Am Fam Physician ; 80(8): 841-6, 2009 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-19835345

RESUMO

Vitamin D deficiency affects persons of all ages. Common manifestations of vitamin D deficiency are symmetric low back pain, proximal muscle weakness, muscle aches, and throbbing bone pain elicited with pressure over the sternum or tibia. A 25-hydroxyvitamin D level should be obtained in patients with suspected vitamin D deficiency. Deficiency is defined as a serum 25-hydroxyvitamin D level of less than 20 ng per mL (50 nmol per L), and insufficiency is defined as a serum 25-hydroxyvitamin D level of 20 to 30 ng per mL (50 to 75 nmol per L). The goal of treatment is to normalize vitamin D levels to relieve symptoms and decrease the risk of fractures, falls, and other adverse health outcomes. To prevent vitamin D deficiency, the American Academy of Pediatrics recommends that infants and children receive at least 400 IU per day from diet and supplements. Evidence shows that vitamin D supplementation of at least 700 to 800 IU per day reduces fracture and fall rates in adults. In persons with vitamin D deficiency, treatment may include oral ergocalciferol (vitamin D2) at 50,000 IU per week for eight weeks. After vitamin D levels normalize, experts recommend maintenance dosages of cholecalciferol (vitamin D3) at 800 to 1,000 IU per day from dietary and supplemental sources.


Assuntos
Deficiência de Vitamina D , Vitamina D/administração & dosagem , Diagnóstico Diferencial , Saúde Global , Humanos , Prevalência , Fatores de Risco , Vitamina D/análogos & derivados , Vitamina D/sangue , Deficiência de Vitamina D/diagnóstico , Deficiência de Vitamina D/tratamento farmacológico , Deficiência de Vitamina D/epidemiologia , Vitaminas/administração & dosagem
3.
J Fam Pract ; 58(9): 460-8, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19744413

RESUMO

Treat systolic hypertension in the elderly to reduce their risk of cardiovascular events and mortality. Don't shy away from treating the very old. Hypertension treatment is beneficial even in patients who are 80 years of age or older. Don't prescribe an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker for elderly patients without heart failure; the combination increases the risk of adverse effects without reducing cardiovascular events.


Assuntos
Anti-Hipertensivos/uso terapêutico , Pressão Sanguínea/fisiologia , Avaliação Geriátrica/métodos , Hipertensão , Fatores Etários , Idoso de 80 Anos ou mais , Prescrições de Medicamentos/normas , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/epidemiologia , Hipertensão/fisiopatologia , Prevalência , Taxa de Sobrevida , Estados Unidos/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...